MoonLake Immunotherapeutics MLTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -77.7%-47.2pp | -60.5%-35.3pp | -54.2%-36.5pp | -40.3%-29.4pp | -30.6%-16.7pp | |
| Return on invested capital | -199.6%-85.6pp | -155.5%-65.3pp | -353.1%-256pp | -132.2%— | -114.1%— | |
| Liquidity | ||||||
| Current ratio | 8.6×-12.5× | 9.3×-11.8× | 8.5×-17.0× | 16.6×-27.1× | 21.1×-41.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.2× | 0.2×+0.2× | 0.3×+0.3× | 0.2×+0.2× | 0.2×+0.2× | |
| Per Share | ||||||
| Book value per share | $3.56-44.7% | $4.72-33.5% | $4.56-41.3% | $5.59-32.5% | $6.44-25.6% | |
| Valuation | ||||||
| Market capitalization | $1.34B-45.9% | $933.77M-72.7% | $455.31M-85.6% | $2.9B+5.5% | $2.47B-21.4% | |
| Price / book | 5.3×-0.8× | 3.1×-4.6× | 1.6×-4.9× | 8.2×+2.9× | 6.1×+0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do MoonLake Immunotherapeutics's ratios come from?
- Every ratio is computed from MoonLake Immunotherapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.